PLK1 Inhibitors for Refractory and Relapsed Cancer Patients
PLK1 inhibitors are increasingly being recognized as a promising treatment option for refractory and relapsed cancer patients. With a growing PLK1 inhibitors pipeline and encouraging clinical trial data, these therapies are poised to become a significant component of cancer treatment regim
